Article info
PDFCommentary
Pembrolizumab plus lenvatinib for all advanced endometrial cancer? Maybe not
- Correspondence to Dr Eduardo Paulino, Brazilian National Cancer Institute, Rio de Janeiro 20081-250, Brazil; dr.eduardopaulino{at}gmail.com
Citation
Pembrolizumab plus lenvatinib for all advanced endometrial cancer? Maybe not
Publication history
- Received January 25, 2022
- Accepted February 7, 2022
- First published February 21, 2022.
Article Versions
- You are currently viewing a Previous version of this article (21 February 2022).
- View the most recent version of this article
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.